KA
ABEO icon

KLCM Advisors’s Abeona Therapeutics ABEO Stock Holding History

KLCM Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,144
Closed -$73K – 78
2016
Q1 		$73K Hold
1,144
– – 0.03% 71
2015
Q4 		$96K Hold
1,144
– – 0.03% 64
2015
Q3 		$116K Buy
1,144
+270
+31% +$35.8K 0.04% 66
2015
Q2 		$111K Buy
+874
New +$131K 0.03% 119

Other funds holding ABEO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KLCM Advisors's ABEO Position: Q2 2016 in Review

KLCM Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2016, closing a stake of 1,144 shares — an estimated $73K sold.

KLCM Advisors first reported a position in ABEO in Q2 2015 and held it in 4 quarters. The position peaked at $116K in Q3 2015. 37 funds tracked by Wall St. Rank hold ABEO as of Q2 2016.

  • KLCM Advisors reported no remaining Abeona Therapeutics position as of Q2 2016 after selling out during the quarter.
  • KLCM Advisors sold 1,144 Abeona Therapeutics shares in Q2 2016, an estimated $73K.
  • KLCM Advisors first reported a position in Abeona Therapeutics in Q2 2015 and held it in 4 quarters.
  • KLCM Advisors's Abeona Therapeutics position peaked at $116K in Q3 2015.
  • 37 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2016.

Based on KLCM Advisors's 13F filing for Q2 2016, filed 8 Aug 2016.